People: Acorda Therapeutics Inc (ACOR.O)
24 Mar 2017
Dr. Andrew R. Blight, Ph.D., is Chief Scientific Officer of Acorda Therapeutics, Inc., since January 2004. He previously served as our Executive Vice President, Research and Development from 2000 to 2004, and Vice President, Research and Development, from 1998 to 2000. Prior to joining Acorda Therapeutics, he spent approximately six years as Professor and Director of the Neurosurgery Research Laboratory at the University of North Carolina at Chapel Hill. Dr. Blight held prior academic positions at Purdue University and New York University. Dr. Blight is a leader in SCI pathophysiology research and has made several important contributions to the field, particularly on the role of demyelination in SCI. He also pioneered the therapeutic application of 4-AP in SCI animal models and in human clinical trials. Dr. Blight is a member of the editorial board of the Journal of Neurotrauma and has served as a member of the NIH NSDA review committee. He was previously Secretary, Treasurer and Vice President of the National Neurotrauma Society. Dr. Blight received his B.S. in Zoology and his Ph.D. in Zoology/Neurobiology from the University of Bristol, U.K.
|Total Annual Compensation, USD||583,723|
|Restricted Stock Awards, USD||229,973|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||670,864|
|Fiscal Year Total, USD||1,484,560|